NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st
Rhea-AI Summary
NEXGEL (NASDAQ:NXGL) announced it will report fourth quarter and full year 2025 financial results after market close on March 31, 2026. Management will host a conference call at 4:30 P.M. ET the same day and provide a live webcast and replay.
Dial-in numbers, replay access code 11161124, and a 90-day archived webcast will be available for investors and analysts.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Acquisition terms | Positive | +5.0% | Outlined consideration terms to license and acquire six biomaterial products. |
| Mar 10 | Definitive acquisition | Positive | -67.6% | Signed definitive agreement for portfolio expected to triple annual revenue. |
| Feb 10 | Acquisition financing | Neutral | +0.0% | Announced $1.797M financing and potential additional $14.869M for acquisition. |
| Dec 16 | Strategic investment | Positive | -0.5% | NexGelRx received strategic investments and added a board observer/advisor. |
| Dec 11 | Spin-off announcement | Positive | +23.1% | Announced spin-off of drug delivery assets into NexGelRx with royalty stake. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent NXGL-related news often showed mixed follow-through: several clearly positive corporate and acquisition updates saw both sharp gains and sharp losses, indicating inconsistent price alignment with headline sentiment.
Over the past several months, NEXGEL-focused news highlighted strategic changes and financing. In December 2025, the company announced the NexGelRx spin-off and a follow-on investment and board observer appointment. In February 2026, it disclosed $1.797 million in acquisition-related financing. In March 2026, it outlined and then finalized terms to acquire a Celularity biomaterials portfolio expected to lift annual revenue to about $35 million. Today’s earnings date announcement fits into this broader execution and integration phase.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management will host a conference call at 4:30 P.M. ET on the same day
LANGHORNE, Pa., March 25, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, after the market close on March 31, 2026. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day.
Fourth Quarter and Full Year 2025 Financial Results Conference Call
Date: March 31, 2026
Time: 4:30 P.M. ET
Live Call: 1-833-316-1983 (U.S. Toll Free) or 1-785-838-9310 (International)
Webcast: Events and Presentations
For interested individuals unable to join the conference call, a replay will be available through April 14, 2026, by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11161124. An archived version of the webcast will also be available for 90 days.
About NEXGEL, INC.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com
